Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer

Osimertinib (Tagrisso, AstraZeneca) is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and irreversibly inhibits EGFR-TKI sensitizing mutations and the T790M mutation; the drug exhibits lower-level activity against wild-type EGFR (1). Recently, the AME Lung Cancer Collaborative Group summarized the current role of osimertinib and made recommendations as to how osimertinib could,